Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome + Capecitabine + Lenvatinib in Advanced BTC
NCT06463548Phase 2Not yet recruiting
- Sponsor
- Yunpeng Liu
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection in biliary tract carcinoma (BTC), sponsored by Yunpeng Liu. Primary endpoint: Progression-free survival at 6 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT06463548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463548.